Auven Therapeutics Announces Initiation of Confirmatory Phase 3 Clinical Trial of Seciera (OTX-101) for the Treatment of Dry Eye Disease

-Study to confirm significant improvements in tear production as sole primary endpoint to support regulatory filing.
-Commercial assessment confirms Seciera has the potential for $1 billion in sales worldwide.

Read the full press release